Abstract:OBJECTIVE:We analyzed data of lupus nephritis (LN) patients to find parameters that can predict remission. METHODS:Sixty-four LN patients who were diagnosed with class III, IV, V or V + III/IV by renal biopsy and were followed up for more than six months in our center were enrolled retrospectively. Receiver operating characteristic curves were used to test the predictive values of urinary protein-to-creatinine ratio (UPCR), serum albumin and complement C3 at the first, second and third months as predictors for remission at the sixth month. RESULTS:The patients' renal pathologies were class III (five cases), class IV (33 cases), class V (nine cases) and class V + III/IV (17 cases). All patients received standard immunosuppressive therapy. Forty-six (71.9%) patients (grouped as the remission group) achieved remission at the end of the sixth month, including 23 complete remissions and 23 partial remissions. The other 18 patients were grouped as the no-remission group. There were no significant differences in clinical data, proportion of immunosuppressive therapy or renal pathological characteristics between the remission group and no-remission group at baseline, except the serum urea nitrogen of the remission group was lower than in the no-remission group. The UPCR were significantly lower in the remission group than in the no-remission group at months 1, 2, 3 and 6, respectively, while the serum albumin was significantly higher in the remission group than in the no-remission group at months 3 and 6, respectively. There were no significant differences in serum creatinine between the remission group and no-remission group, except at month 1. The C3 levels were higher in the remission group than in the no-remission group at months 1, 2 and 3, respectively. The areas under the curve (AUC) of the change percentage of UPCR at month 3 and the serum albumin at month 3 were the most significant (AUC 0.778, p = 0.002; AUC 0.773, p = 0.001, respectively). The cutoff value of the change percentage of UPCR at month 3 was 59%. The cutoff value of serum albumin at month 3 was 32.9g/l. CONCLUSION:The change percentage of UPCR ≥59% and the serum albumin ≥32.9 g/l at the third month were valuable for predicting remission at the sixth month in LN. Because of the small-size and retrospective nature, this study needs to be validated.

Expression of Monocyte Chemoattractant Protein-1 in Lupus Nephritis and Its Clinical Significance

Study on the Level of Urine MCP-1 and Cellular Immunity and the Relativity Between Them

Monocyte Chemotactic Protein-1, Fractalkine, and Receptor for Advanced Glycation End Products in Different Pathological Types of Lupus Nephritis and Their Value in Different Treatment Prognoses.

Early-stage predictors for treatment responses in patients with active lupus nephritis.

The Association of Urinary MCP-1 with Disease Activity of Lupus Nephritis

Expression and clinical significance of TLR9 and Mcp-1 in renal tissue of patients with lupus

Monocyte Chemoattractant Protein-1 Expression in Renal Tissue is Associated with Monocyte Recruitment and Tubulo-Interstitial Lesions in Patients with Lupus Nephritis.

Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis

Serum Levels of Chemokines in the Patients With Systemic Lupus Erythematosus

Peripheral blood T-cell subset and its clinical significance in lupus nephritis patients

Expression of RNATES,MCP-1 in serum and synovial fluid in patients with rheumatoid arthritis and its clinical significance

Combined Detection of Umcp-1 and Utweak for Rapid Discrimination of Severe Lupus Nephritis.

The study of chemokines and chemokine receptors expression in patients with proliferative lupus nephritis

Combined Utilization of Untimed Single Urine of MCP-1 and TWEAK As a Potential Indicator for Proteinuria in Lupus Nephritis

The Expression of Monocyte Chemoattractant Protein-1 in Children with Henoch-Schonlein Purpura Nephritis

Chemokine CXCL1 as a potential marker of disease activity in systemic lupus erythematosus

Roles of chemokine associated measurement in serum and urine in systemic lupus erythematosus

Expression of CXCL8/IL-8 in the urine and serum specimens of patients with systemic lupus erythematosus

The changes and clinical significance of monocyte chemoattractant protein-1 in iga nephropathy

Composite Urinary Biomarkers to Predict Pathological Tubulointerstitial Lesions in Lupus Nephritis.

Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritis